Fig. 2: SARS-CoV-2-specific humoral immunity.

a Total anti-RBD antibodies expressed as AUC. b SARS-CoV-2-specific ADCC expressed as percentage. c SARS-CoV-2-specific neutralizing activity expressed as half maximal inhibitory plasma dilution (ID50). Red/blue dots: individual values; red/blue lines connecting median values at T0 and T1; longitudinal analyses (T1 compared to T0): Wilcoxon signed-rank test (P values in red/blue); cross-sectional analyses (at each time point): Mann–Whitney U test (P values in black); EPS− (T0, T1): n = 10, 10; EPS+ (T0, T1): n = 37 (ADCC and ID50) or 38 (Abs); dotted lines: median of 7 pre-pandemic healthy controls. Statistical significance at p-value < 0.05.